Delayed surgical resection of central nervous system germ cell tumors. 2002

Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
Department of Neurosurgery, New York University Medical Center, New York Presbyterian Hospital, New York, New York 10016, USA. howard.weiner@med.nyu.edu

OBJECTIVE To determine the value of delayed surgical resection in patients with central nervous system germ cell tumors who exhibit less than complete radiographic response despite declining serum and cerebrospinal fluid (CSF) tumor markers after initial chemotherapy. METHODS We retrospectively analyzed 126 patients enrolled on two international multicenter clinical trials (the First and Second International Central Nervous System Germ Cell Tumor Studies) for patients with newly diagnosed central nervous system germ cell tumors. After at least three cycles of chemotherapy, 10 of these patients underwent delayed surgical resection owing to evidence of residual radiographic abnormalities despite declining or completely normalized serum and CSF levels of alpha-fetoprotein and human chorionic gonadotropin. RESULTS Eight of these patients demonstrated nongerminomatous germ cell tumor elements at the time of initial diagnosis. In these patients, either serum or CSF tumor markers were elevated initially. Two patients demonstrated pure germinomas with normal levels of serum and CSF tumor markers. After chemotherapy, radiographic evaluation revealed a partial response in seven patients, a minor response in one patient, and stable disease in two patients. All 10 patients had either normal or decreasing levels of serum and CSF tumor markers before second-look surgery. At delayed surgical resection, 7 of the 10 patients underwent gross total resection, and 3 patients underwent subtotal resection of residual lesions. Pathological findings at second-look surgery demonstrated three patients to have mature teratomas, two with immature teratomas, and five with necrotic or scar tissue alone. To date, 7 of the 10 patients have had no recurrence during an average follow-up time of 36.9 months (range, 3-96 mo). Three of four patients with nongerminomatous germ cell tumors who had tumor markers that were decreased, but not normalized, before second-look surgery eventually developed tumor dissemination/progression, and they required subsequent radiation therapy despite having teratoma or necrosis/scar tissue at delayed surgery. In contrast, three of four patients with nongerminomatous germ cell tumors and completely normalized markers did not progress and did not require radiation therapy. CONCLUSIONS Delayed surgical resection should be considered in patients with central nervous system germ cell tumors who have residual radiographic abnormalities and normalized tumor markers, because these lesions are likely to be teratoma or necrosis/scar tissue. However, second-look surgery should be avoided in patients whose tumor markers have not normalized completely.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015337 Multicenter Studies as Topic Works about controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children. Multicenter Trials,Multicentre Studies as Topic,Multicentre Trials,Multicenter Trial,Multicentre Trial,Trial, Multicenter,Trial, Multicentre,Trials, Multicenter,Trials, Multicentre
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses

Related Publications

Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
December 2002, Neurosurgery,
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
March 2002, Current treatment options in neurology,
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
April 1998, Seminars in oncology,
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
August 2010, Journal of neurosurgery. Pediatrics,
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
December 2003, Current treatment options in oncology,
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
December 2005, No to shinkei = Brain and nerve,
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
January 2022, Frontiers in oncology,
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
November 2014, Current opinion in oncology,
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
January 1997, Neurologia (Barcelona, Spain),
Howard L Weiner, and Roger A Lichtenbaum, and Jeffrey H Wisoff, and Robert B Snow, and Mark M Souweidane, and Jeffrey N Bruce, and Jonathan L Finlay
April 2008, Neurosurgical review,
Copied contents to your clipboard!